GLOWBlend
GHK-Cu + BPC-157 + TB-500 skin & recovery blend.
- Status
- Research / not approved
- Developer
- Compounded research-peptide blend; vendor-specific
- Receptors / target
- Not a single target — combines GHK-Cu (skin/collagen remodeling), BPC-157 (cytoprotection) and TB-500 (actin regulation & angiogenesis); no characterized combined pharmacology
- FDA-approved?
- NO
- Prescription available?
- NO
- Studied for
- skin & collagen / tissue research (GHK-Cu)soft-tissue / tendon / ligament repair (BPC-157)wound healing & angiogenesis (TB-500)recovery & anti-inflammatory research
Overview
GLOW is a compounded research-peptide blend combining three repair-oriented peptides — GHK-Cu, BPC-157 and TB-500 — in a single vial, most commonly at a 50/10/10 mg ratio (total ~70 mg), though strength and ratio vary by vendor. The "GLOW" name reflects its positioning around skin, tissue-repair and recovery research rather than any approved indication. It is sold research-use-only; no clinical trials have studied this combination, and all evidence is per individual component.
Mechanism
The three peptides act through distinct, complementary pathways. GHK-Cu is a copper-binding tripeptide that up-regulates collagen, elastin and tissue-remodeling/angiogenic genes; BPC-157 is a synthetic gastric pentadecapeptide studied for soft-tissue repair and anti-inflammatory signaling; and TB-500 is a synthetic thymosin-beta-4 fragment that promotes cell migration and angiogenesis via actin regulation. The rationale is additive coverage of overlapping repair processes, but the combined pharmacology has not been characterized.
Clinical evidence
There are no human trials of the GLOW blend; efficacy claims rest entirely on the individual components. GHK-Cu has the most direct human/skin data (largely small topical/cosmetic studies, with one independent RCT showing no objective benefit after laser resurfacing), while BPC-157 and TB-500 efficacy is overwhelmingly preclinical — animal and in-vitro repair models with little to no controlled human injectable data. No peer-reviewed evidence supports the specific three-peptide combination, its dosing, or claimed synergy.
Safety profile
The combined-injection safety of GLOW has not been studied. BPC-157 and TB-500 lack robust human safety data and remain unapproved investigational compounds, and TB-500 (thymosin beta-4) is prohibited in sport by WADA at all times, so GLOW is banned in sport. GHK-Cu's copper content raises theoretical concerns with cumulative or high-dose use. Reported effects are mostly local (injection-site reactions) with limited long-term human data. Research-use only; not FDA-approved, and nothing here is therapeutic or dosing guidance.
- Weeks
No trials of the blend. GHK-Cu skin effects are studied over weeks (topical); BPC-157/TB-500 are anecdotal/animal. TB-500 makes the blend WADA-prohibited. Any timeline is unverified.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Injection-site reactions (redness, irritation, swelling)
- Limited long-term human safety data
- Theoretical copper-related effects (GHK-Cu)
- Unstudied combined-injection safety
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- No human safety data exist for the blend; the combination is uncharacterized and research-use only.
- GHK-Cu carries copper; cumulative or high-dose use raises theoretical copper-overload concerns, especially in those with Wilson's disease or copper-metabolism disorders.
- BPC-157 and TB-500 are pro-angiogenic in preclinical models, raising a theoretical concern in the setting of active or prior malignancy.
- No documented human drug interactionsNo interaction studies of the combination; uncharacterized in humans (research use only)
Compare
- vs KLOW
Sibling blend — GLOW plus KPV added for an extra anti-inflammatory component.
- vs Wolverine
Related repair-oriented blend; compare component makeup and ratios.
- vs GHK-Cu
The single GHK-Cu component, which has the most direct human/skin data of the three.
FAQ
Is the GLOW blend studied in clinical trials?
No. There are no clinical trials of the GLOW combination. All evidence is per individual component (GHK-Cu, BPC-157, TB-500), and BPC-157/TB-500 efficacy is largely preclinical. Any synergy is hypothesized, not demonstrated.
What is in GLOW?
Three repair-oriented peptides in one vial — GHK-Cu, BPC-157 and TB-500 — most commonly at a 50/10/10 mg ratio, though strength and ratio vary by vendor.
Is GLOW banned in sport?
Yes. It contains TB-500 (thymosin beta-4), which is on the WADA Prohibited List at all times, so GLOW is prohibited in sport.
Why combine GHK-Cu, BPC-157 and TB-500?
The rationale is additive coverage of overlapping repair pathways — GHK-Cu for collagen/skin remodeling, BPC-157 for cytoprotection and soft-tissue signaling, TB-500 for cell migration and angiogenesis. It is a hypothesis about complementary mechanisms, not a tested combination; the blend's combined pharmacology has not been characterized.
How is GLOW administered?
It is a compounded multi-peptide vial reported to be reconstituted and injected subcutaneously. There is no validated dosing or route for the blend; the combined-injection safety and sterility of compounded multi-peptide vials are not established. Research use only.
How does GLOW differ from KLOW?
KLOW is the same three peptides plus KPV — an anti-inflammatory tuftsin/alpha-MSH-derived tripeptide — added as a fourth component. Both are unstudied as blends and both contain TB-500, so both are WADA-prohibited; the difference is KLOW's extra anti-inflammatory peptide.
Related guides
ArticleGLOW vs KLOW: Which Peptide Blend Is Better? The KPV DifferenceSimilar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.